La vendita allo scoperto per Keurig Dr Pepper dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Keurig Dr Pepper. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Keurig Dr Pepper (NASDAQ:KDP) Azioni, Report sulle vendite allo scoperto

Keurig Dr Pepper

Dr Pepper Snapple Group

Keurig Dr Pepper was established in 2018 following a merger between Keurig Green Mountain Coffee and Dr Pepper Snapple. The company manufactures and distributes coffee systems (including coffee brewers and single-serve coffee pods) under the Keurig and Green Mountain brands, as well as ready-to-drink beverages including flavored (non-cola) sparkling soft drinks under well-known brands such as Dr Pepper, Snapple, and Canada Dry. The company controls production and route to market for its own brands through in-house manufacturing plants and distribution infrastructure and leverages these facilities to manufacture and distribute for third-party coffee and beverage brands via licensing and partnership agreements. US and Canada make up 95% of revenues, with the rest from Mexico.

Keurig Dr Pepper Inc

KEURIG DR PEPPER ORD

RBC Capital analyst Jon Arfstrom reiterates Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Outperform and maintains $17 price target.

News

Price Target

Reiteration

Analyst Ratings

HBAN

RBC Capital Reiterates Outperform on Huntington Bancshares, Maintains $17 Price Target

Procter &amp; Gamble Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) shares are trading lower after the company reported&nbsp;first-quarter&nbsp;sales of&nbsp;$21.74 billion&nbsp;(-1% Y/Y),&nbsp;missing the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41399117/p-g-announces-fiscal-year-2025-first-quarter-results" rel="noreferrer noopener">consensus estimate of&nbsp;$21.91 billion</a>.
Organic sales, which exclude the impacts of foreign exchange and acquisitions and divestitures, increased&nbsp;by 2%.
Organic sales growth was driven by a 1% increase in higher pricing and a 1% rise in organic volume, excluding the effects of acquisitions and divestitures.
Sales in the Beauty segment fell&nbsp;5%, and the Baby, Feminine &amp; Family Care segment declined 2%.
Meanwhile, the Grooming segment sales sales remained flat, while Fabric &amp; Home Care grew 1% and Health Care sales increased&nbsp;2%.
Gross profit remained flat&nbsp;at $11.3 billion. The reported gross margin expanded by 10 basis points to&nbsp;52.1%, and the core gross margin was flat year-over-year.
Gains included 170 basis points from productivity savings and 30 basis points from pricing, offset by 90 basis points from higher commodity costs, 60 basis points from unfavorable mix, and 40 basis points from product reinvestments.
Operating margin expanded 30 basis points to&nbsp;26.7% while operating income for the quarter rose 1%&nbsp;to&nbsp;$5.80 billion.
Adjusted EPS of&nbsp;$1.93 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the analyst consensus of&nbsp;$1.90.</a>
P&amp;G held&nbsp;$12.16 billion&nbsp;in cash and equivalents as of September 30. Operating cash flow for the quarter was&nbsp;$4.3 billion.
The company returned around $4.4&nbsp;billion&nbsp;of value to shareholders via&nbsp;$2.4 billion&nbsp;in dividend payments and&nbsp;$1.9 billion&nbsp;of share repurchases.
&#8220;We remain committed to our integrated growth strategy of a focused product portfolio of daily use categories where performance drives brand choice, superiority — across product performance, packaging, brand communication, retail execution and consumer and customer value — productivity, constructive disruption and an agile and accountable organization,&#8221; said Board Chairman, President, and CEO Jon Moeller.
Outlook: P&amp;G reaffirmed FY25 guidance for all-in sales growth of&nbsp;2%&nbsp;–&nbsp;4%&nbsp;and <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">organic sales growth of&nbsp;3%&nbsp;–&nbsp;5%</a>.
This&nbsp;outlook equates to FY25 revenue of&nbsp;$85.72 billion&nbsp;–&nbsp;$87.40 billion&nbsp;(versus an estimate of&nbsp;$86.06 billion) and adjusted EPS of&nbsp;$6.91&nbsp;–<a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/40037468/why-gillette-parent-procter-gamble-shares-are-tumbling-today" rel="noreferrer noopener"> $7.05&nbsp;(vs. consensus of $6.97)</a>.
P&amp;G reaffirmed its outlook for adjusted free cash flow productivity of&nbsp;90%, payment of around&nbsp;$10 billion in dividends and repurchasing&nbsp;$6 billion to&nbsp;$7 billion of common shares in fiscal 2025.
Investors can gain exposure to the stock via&nbsp;iShares U.S. Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYK#NYSE">IYK</a>) and Fidelity MSCI COnsumer Staples Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSTA#NYSE">FSTA</a>).
Price Action: PG shares are down 0.81% at $170.88 premarket at the last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41397178/procter-gamble-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earning" target="_blank" rel="noreferrer noopener">Procter &amp; Gamble Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Earnings

Equities

Large Cap

Guidance

Dividends

Buybacks

Movers

FSTA

iShares Trust Dow Jones USnsumer Goods Sector Index Fund

Procter & Gamble's Mixed Bag Q1: EPS Exceeds Estimates, Reaffirms Growth Outlook & More

Macquarie analyst Tim Nollen maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and maintains $795 price target.

NFLX

Macquarie Maintains Outperform on Netflix, Maintains $795 Price Target

Biotech

General

ARQT

Arcutis Gains Health Canada Approval For ZORYVE Foam 0.3% To Treat Seborrheic Dermatitis In Patients Aged 9 And Older; Marks First New Mechanism Topical Treatment For Condition In Canada In Over 20 Years

Susquehanna analyst Biju Perincheril maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Positive and lowers the price target from $78 to $77.

Susquehanna Maintains Positive on Occidental Petroleum, Lowers Price Target to $77

~10% Shareholder Believes Proposed Sale Represents an Egregious "Take Under" and Significantly Undervalues the Company
Urges the Board to Consider Shareholders' Best Interests and Disclose the Company's 2025 Projections so Investors Can Accurately Value the Company Against the Deal Price
Bradley L. Radoff, who collectively with his affiliates owns approximately 9.9% of the outstanding shares of GSE Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVP#NASDAQ">GVP</a>) ("GSE" or the "Company"), today sent the below letter to GSE Systems' Board of Directors (the "Board") indicating its opposition to the proposed take-private merger with Pelican Energy Partners ("Pelican").
&#x2A;&#x2A;&#x2A;
GSE Systems, Inc. 6940 Columbia Gateway Drive, Suite 470 Columbia, MD 21046 Attention: The Board of Directors
October 18, 2024
Members of the Board,
I am one of GSE's largest shareholders, with an approximately 9.9% stake in the Company. After reviewing the Company's belated and limited disclosures, I believe the proposed sale to Pelican significantly undervalues the Company and puts leadership's interests ahead of shareholders' best interests.
The Board, which collectively has limited public company experience and de minimis share ownership, appears to have allowed the Company to develop liquidity issues that have become the basis for what is seemingly a fire sale. Now, with this deal, the Board is seemingly doubling down on its missteps by giving up on the Company right as the nuclear power industry is entering a renaissance that should be a significant tailwind for GSE and its prospects for enhanced value creation.
Despite GSE's apparent runway for improved financial performance, you have refused to provide a view on the business for 2025. As a result, shareholders are unable to appropriately analyze the Company's prospects and evaluate a standalone future relative to the current deal. The Board's contention that it cannot provide projections because management's forecasts have historically been unreliable simply serves as an acknowledgment of your failures when it comes to governing the business and overseeing the executive leadership you put in place.
With respect to your decision to deprive shareholders of relevant information, it is highly unusual that the Company's definitive proxy statement for the merger did not contain forward-looking business projections. I appear to be one of the many shareholders who are disappointed with this insufficient disclosure. The Company's Form-8-K filed on October 8th, 2024 – just two weeks prior to the shareholder vote – was purportedly only put out in response to "demand letters alleging similar deficiencies and/or omissions regarding the disclosures made in the Preliminary Proxy Statement or the Definitive Proxy Statement."1
In the October 8th 8-K, GSE provided a mere glimpse of very encouraging and positive projections that implied more than $0.30 of quarterly earnings for a Company that currently trades at around $4. The projections, while incomplete, appear to show that the Company is beginning to materially benefit from the nuclear resurgence. Given this context, I am calling on you to provide the market with customary disclosures regarding the Company's forward-looking projections so shareholders can make the most informed decision on the transaction. If the Company continues to provide such limited disclosures as it did in the October 8th 8-K, then it should at least reset the record date for the Pelican merger to enable the investment community to sufficiently digest this new, albeit limited, information.
While the Company's legal counsel and bankers – who stand to make millions if the deal goes through – may have signed off on the disclosures to this point, the Board should know that this deal fails the smell test. Nothing in the merger agreement prevents you from providing more information and transparency to shareholders. I believe your decision to effectively keep GSE shareholders in the dark will define your directorship at GSE and be a black mark for any of you who intend to pursue other director opportunities. Shareholders have long memories.
While you have trumpeted Institutional Shareholder Services' recent report as an endorsement, I don't believe shareholders should give it any credence. The report neglects to mention the lack of initial projections, the magnitude of the late projections and the recent trading activity indicating that shareholders believe there is more value than is being offered by Pelican. In fact, approximately 30% of the Company's outstanding shares have traded at or above the deal price this week.
In closing, I believe an independent GSE has significant upside potential. The Board failed to provide projections prior to the record date and then reluctantly offered limited disclosure just two weeks prior to the shareholder meeting. This set of circumstances, combined with a comical fairness opinion and egregious transaction expenses, are very troubling. I once again demand normal course forward projections so that shareholders, who are the owners of the business, can fairly evaluate the Pelican transaction.
Sincerely,
Bradley L. Radoff

Management

~10% Shareholder Bradley L. Radoff Issues Open Letter To GSE Systems' Board Of Directors To State Opposition To Proposed Sale To Pelican Energy Partners; Believes Proposed Sale Represents An Egregious "Take Under" And Significantly Undervalues The Company

Susquehanna analyst Biju Perincheril maintains Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) with a Neutral and raises the price target from $149 to $154.

Susquehanna Maintains Neutral on Hess, Raises Price Target to $154

Rosenblatt analyst Barton Crockett maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Neutral and raises the price target from $635 to $680.

Rosenblatt Maintains Neutral on Netflix, Raises Price Target to $680

Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZURA#NASDAQ">ZURA</a>) with a Overweight.

ZURA

Cantor Fitzgerald Reiterates Overweight on Zura Bio

As of Oct. 18, 2024, two stocks in the communication services sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">T-Mobile Us Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)</h3>
<ul>
<li>T-Mobile announced redemption of Sprint 7.625% notes due Feb. 15, 2025. The company's stock gained around 13% over the past month and has a <a href="https://www.benzinga.com/quote/TMUS">52-week high of $222.73</a>.</li>
<li>RSI Value: 82.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TMUS Price Action: Shares of T-Mobile Us gained 1% to close at $221.95 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>)</h3>
<ul>
<li>Sify Technologies will announce financial results for the second quarter on Tuesday, Oct. 22. The company's stock gained around 54% over the past month and <a href="https://www.benzinga.com/quote/SIFY">has a 52-week high</a> of $12.30.</li>
<li>RSI Value: 70.98</li>
<li>SIFY Price Action: Shares of Sify rose 14.8% to close at $3.73 on Thursday. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

SIFY

TMUS

Top 2 Tech And Telecom Stocks That May Crash In Q4

Susquehanna analyst Biju Perincheril maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Positive and lowers the price target from $237 to $233.

FANG

Susquehanna Maintains Positive on Diamondback Energy, Lowers Price Target to $233

One step closer to achieving public reimbursement of AMVUTTRA&#xAE; for hATTR patients in Canada
MISSISSAUGA, ON, Oct. 18, 2024 /CNW/ - Alnylam Canada ULC is pleased to announce that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of AMVUTTRA&#xAE; (vutrisiran injection), an RNAi therapeutic administered by quarterly subcutaneous injection, for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).1&nbsp;This comes following a positive recommendation from the Canadian Drug Agency (CDA) and the Institut national d'excellence en santé et services sociaux (INESSS), and signals the next step in the process where individual participating provinces and territories will start to list&nbsp;AMVUTTRA&#xAE; on their formularies.

Global

ALNY

Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults

Susquehanna analyst Biju Perincheril maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Positive and lowers the price target from $63 to $62.

Susquehanna Maintains Positive on Devon Energy, Lowers Price Target to $62

Telsey Advisory Group analyst Dana Telsey maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Outperform, adjusts target to $183 from $183 (forward stock split 6:1).

DECK

Telsey Advisory Group Maintains Outperform on Deckers Outdoor, Adjusts Price Target To $183 (forward stock split 6:1)

Susquehanna analyst Biju Perincheril maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Positive and lowers the price target from $147 to $144.

Susquehanna Maintains Positive on ConocoPhillips, Lowers Price Target to $144

Cantor Fitzgerald analyst Andres Sheppard initiates coverage on PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) with a Overweight rating and announces Price Target of $14.

Initiation

Cantor Fitzgerald Initiates Coverage On PureCycle Technologies with Overweight Rating, Announces Price Target of $14

<a href="https://www.aljazeera.com/news/liveblog/2024/10/18/live-israel-says-hamas-chief-yahya-sinwar-killed-war-on-gaza-to-continue" title="https://www.aljazeera.com/news/liveblog/2024/10/18/live-israel-says-hamas-chief-yahya-sinwar-killed-war-on-gaza-to-continue">https://www.aljazeera.com/news/liveblog/2024/10/18/live-israel-says-hamas-chief-yahya-sinwar-killed-war-on-gaza-to-continue</a>

Macro Economic Events

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Hamas Senior Official Al-Hayya Says Group Is Continuing Path Until Achieving Palestinian People's Ambitions; Says Sinwar's Death Will Turn Into A Curse On 'The Occupiers'; Sinwar's Death Will Only Strengthen The Group; Israeli Hostages Will Not Return Until Aggression On Gaza Stops And Withdrawal Of Israeli Forces

Susquehanna analyst Biju Perincheril maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Positive and lowers the price target from $52 to $48.

Susquehanna Maintains Positive on APA, Lowers Price Target to $48

WIIM

DRUG

Bright Minds Biosciences shares are trading higher. The company announced a $35 million non-brokered private placement.

<h3>Gainers</h3>
<ul>
<li>Lion Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGHL#NASDAQ">LGHL</a>) shares rose 29.8% to $0.27 during Friday's pre-market session. The company's market cap stands at $1.8 million. </li>
<li>Prestige Wealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWM#NASDAQ">PWM</a>) stock moved upwards by 12.49% to $0.9. The market value of their outstanding shares is at $10.8 million. </li>
<li>UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) stock moved upwards by 9.74% to $7.88. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) stock increased by 9.54% to $6.08. The company's market cap stands at $528.5 million. </li>
<li>Garden Stage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIW#NASDAQ">GSIW</a>) stock rose 7.23% to $1.63. The market value of their outstanding shares is at $25.4 million. </li>
<li>LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) shares rose 7.01% to $3.05. The market value of their outstanding shares is at $501.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pineapple Financial (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#AMEX">PAPL</a>) shares declined by 8.3% to $0.66 during Friday's pre-market session. The company's market cap stands at $4.8 million. </li>
<li>Netcapital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) shares declined by 5.15% to $1.66. The company's market cap stands at $1.2 million. </li>
<li>Santech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEC#NASDAQ">STEC</a>) stock declined by 4.89% to $1.51. The company's market cap stands at $42.3 million. </li>
<li>Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) stock declined by 4.18% to $90.0. The company's market cap stands at $9.9 billion. The company's, Q3 earnings came out yesterday. </li>
<li>New York Community (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) stock decreased by 4.12% to $11.87. The market value of their outstanding shares is at $4.9 billion. </li>
<li>MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNGD#NYSE">FNGD</a>) stock decreased by 3.62% to $19.47. 
See Also: <a href="http://www.benzinga.com/money/best-financial-services-stocks/" title="www.benzinga.com/money/best-financial-services-stocks/">www.benzinga.com/money/best-financial-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FNGD

GSIW

LGHL

NCPL

NYCB

PAPL

STEC

TIGR

12 Financials Stocks Moving In Friday's Pre-Market Session

Consumer staples with lowest quant rating are worst performers in Q3: DLTR, DG, LW

PepsiCo Q3 Results Preview: Company's EPS Streak Potentially Under Threat

PepsiCo earnings preview: Which levers can be pulled to catch up to Coca-Cola?

PepsiCo trades lower after warning on subdued growth, geopolitical tension

Top quant rated consumer staple stocks ahead of Q3 results

In a report released yesterday, Christopher Carey from Wells Fargo maintained a Buy rating on Keurig Dr Pepper (KDP – Research Report), with a pric...

Keurig Dr Pepper (KDP) Receives a Buy from Wells Fargo

CPI read: Food inflation steps up in September as eggs, butter, and beef prices jump

Buy Keurig Dr Pepper As It Offers Solid Value Relative To Its Peers

Keurig Dr Pepper Is A Solid Business Operating In A Tough Environment

In a report released on October 16, Andrea Faria Teixeira from J.P. Morgan maintained a Buy rating on Keurig Dr Pepper (KDP – Research Report), wit...

J.P. Morgan Sticks to Its Buy Rating for Keurig Dr Pepper (KDP)

BRBR

BRFS

CALM

CELH

COST

DLTR

FTXG

INGR

JJSF

KVUE

LANC

MDLZ

MNST

POST

SMPL

XLRE

Press Releases

Keurig Dr Pepper Highlights Meaningful Progress Towards Ambitious Commitments in Latest Corporate Responsibility Report

Keurig Dr Pepper to Report Second Quarter 2024 Results and Host Conference Call

Keurig Dr Pepper Reports Q2 2024 Results and Reaffirms Fiscal 2024 Guidance

Café Valley Introduces 7UP® and Crush® Orange Flavored Soda Mini Cupcakes

Entertainment

Dr Pepper® Kicks-Off College Football Season with the Return of 'Fansville' and a Fashion Collaboration with Nigel Xavier

Keurig Dr Pepper to Participate in Barclays Global Consumer Staples Conference

Keurig Dr Pepper Announces Multi-Year Sponsorship of the Men's and Women's Mexican National Teams in the U.S.

Black Rifle Coffee Company Announces Long-Term Sales and Distribution Agreement with Keurig Dr Pepper for Black Rifle Energy™ Drinks

Keurig Dr Pepper Increases its Dividend by 7.0% and Declares Quarterly Dividend for Q3 2024

Keurig Dr Pepper to Report Third Quarter 2024 Results and Host Conference Call

BRCC

Embotelladora Andina S.A. Common Stock

Celsius Holdings

The Vita Coco Company, Inc. - Common Stock

Vita Coco

Coca-Cola Consolidated, Inc. - Common Stock

Coca-Cola Consolidated

National Beverage

Fomento Economico Mexicano S.A.B. de C.V. Common Stock

Fomento Economico

Coca-Cola

Coca Cola Femsa S.A.B. de C.V. American Depositary Shares, each representing 10 Units (each Unit consists of 3 Series B Shares and 5 Series L Shares)

Comments

Keurig Dr Pepper

Vendite allo scoperto

Keurig Dr Pepper (NASDAQ:KDP) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO